Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer
Background : Postsurgical treatment with tamoxifen has been shown to improve overall survival among patients with early stage breast cancer. However, the optimal duration of tamoxifen treatment remains controversial. Purpose : A multicenter, randomized trial was initiated in Sweden in the early 1980...
Published in: | JNCI Journal of the National Cancer Institute |
---|---|
Main Author: | |
Format: | Text |
Language: | English |
Published: |
Oxford University Press
1996
|
Subjects: | |
Online Access: | http://jnci.oxfordjournals.org/cgi/content/short/88/21/1543 https://doi.org/10.1093/jnci/88.21.1543 |
id |
fthighwire:oai:open-archive.highwire.org:jnci:88/21/1543 |
---|---|
record_format |
openpolar |
spelling |
fthighwire:oai:open-archive.highwire.org:jnci:88/21/1543 2023-05-15T17:40:19+02:00 Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer Swedish Breast Cancer Cooperative Group 1996-11-06 00:00:00.0 text/html http://jnci.oxfordjournals.org/cgi/content/short/88/21/1543 https://doi.org/10.1093/jnci/88.21.1543 en eng Oxford University Press http://jnci.oxfordjournals.org/cgi/content/short/88/21/1543 http://dx.doi.org/10.1093/jnci/88.21.1543 Copyright (C) 1996, National Cancer Institute ARTICLES TEXT 1996 fthighwire https://doi.org/10.1093/jnci/88.21.1543 2013-05-27T10:10:11Z Background : Postsurgical treatment with tamoxifen has been shown to improve overall survival among patients with early stage breast cancer. However, the optimal duration of tamoxifen treatment remains controversial. Purpose : A multicenter, randomized trial was initiated in Sweden in the early 1980s to compare 2 years with 5-years of adjuvant tamoxifen in the treatment of postmenopausal women younger than 75 years of age who had early stage, axillary lymph node-negative or -positive, invasive disease. Methods : The trial was planned and organized by the Swedish Breast Cancer Group, and it involved five regional breast cancer study organizations (South Sweden, South-East Sweden, Stockholm, Uppsala-Örebro, and North Sweden). During the period from 1983 through 1991, a total of 3887 patients were entered in the trial; 3545 (91%) women remained alive and recurrence free at 2 years and could thus contribute meaningful information to the 2-year (n = 1801) versus 5 year (n = 1744) comparison. Primary surgery consisted of either modified radical mastectomy or breast-conserving surgery. Radiation therapy was indicated for patients with lymph node-positive disease and was generally offered to all women who were treated with breast-conserving surgery. Only 89 (2.5%) of the 3545 women who were recurrence free at 2 years received adjuvant chemotherapy concurrently with tamoxifen. Twenty-milligram daily doses of tamoxifen were used at two centers, and 40-mg daily doses were used at the remaining three centers. Estrogen receptor status of the tumor was known for 2987 women (77% of the entered patients). Primary end points in the trial were event-free survival (local-regional recurrence, distant metastasis, contralateral breast cancer, or death) and overall survival. Survival curves were estimated by use of the life-table method. The Cox proportional hazards model was used to make comparisons between the 2- and 5-year treatment groups. Results : Patients assigned to receive 5 years of tamoxifen, compared with 2 years of ... Text North Sweden HighWire Press (Stanford University) JNCI Journal of the National Cancer Institute 88 21 1543 1549 |
institution |
Open Polar |
collection |
HighWire Press (Stanford University) |
op_collection_id |
fthighwire |
language |
English |
topic |
ARTICLES |
spellingShingle |
ARTICLES Swedish Breast Cancer Cooperative Group Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
topic_facet |
ARTICLES |
description |
Background : Postsurgical treatment with tamoxifen has been shown to improve overall survival among patients with early stage breast cancer. However, the optimal duration of tamoxifen treatment remains controversial. Purpose : A multicenter, randomized trial was initiated in Sweden in the early 1980s to compare 2 years with 5-years of adjuvant tamoxifen in the treatment of postmenopausal women younger than 75 years of age who had early stage, axillary lymph node-negative or -positive, invasive disease. Methods : The trial was planned and organized by the Swedish Breast Cancer Group, and it involved five regional breast cancer study organizations (South Sweden, South-East Sweden, Stockholm, Uppsala-Örebro, and North Sweden). During the period from 1983 through 1991, a total of 3887 patients were entered in the trial; 3545 (91%) women remained alive and recurrence free at 2 years and could thus contribute meaningful information to the 2-year (n = 1801) versus 5 year (n = 1744) comparison. Primary surgery consisted of either modified radical mastectomy or breast-conserving surgery. Radiation therapy was indicated for patients with lymph node-positive disease and was generally offered to all women who were treated with breast-conserving surgery. Only 89 (2.5%) of the 3545 women who were recurrence free at 2 years received adjuvant chemotherapy concurrently with tamoxifen. Twenty-milligram daily doses of tamoxifen were used at two centers, and 40-mg daily doses were used at the remaining three centers. Estrogen receptor status of the tumor was known for 2987 women (77% of the entered patients). Primary end points in the trial were event-free survival (local-regional recurrence, distant metastasis, contralateral breast cancer, or death) and overall survival. Survival curves were estimated by use of the life-table method. The Cox proportional hazards model was used to make comparisons between the 2- and 5-year treatment groups. Results : Patients assigned to receive 5 years of tamoxifen, compared with 2 years of ... |
format |
Text |
author |
Swedish Breast Cancer Cooperative Group |
author_facet |
Swedish Breast Cancer Cooperative Group |
author_sort |
Swedish Breast Cancer Cooperative Group |
title |
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
title_short |
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
title_full |
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
title_fullStr |
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
title_full_unstemmed |
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer |
title_sort |
randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer |
publisher |
Oxford University Press |
publishDate |
1996 |
url |
http://jnci.oxfordjournals.org/cgi/content/short/88/21/1543 https://doi.org/10.1093/jnci/88.21.1543 |
genre |
North Sweden |
genre_facet |
North Sweden |
op_relation |
http://jnci.oxfordjournals.org/cgi/content/short/88/21/1543 http://dx.doi.org/10.1093/jnci/88.21.1543 |
op_rights |
Copyright (C) 1996, National Cancer Institute |
op_doi |
https://doi.org/10.1093/jnci/88.21.1543 |
container_title |
JNCI Journal of the National Cancer Institute |
container_volume |
88 |
container_issue |
21 |
container_start_page |
1543 |
op_container_end_page |
1549 |
_version_ |
1766141205442199552 |